Title: A Pitch, a Portfolio Company, and a Disturbing Case of Imitation
A recent experience has prompted me to open a discussion about the ethics and diligence involved in venture funding and startup competition. This post is intended to be anonymized, focusing on lessons learned and soliciting advice from fellow founders and investors.
Overview
– I’m the founder of a pre-revenue, post-product startup currently raising a seed round.
– We have been actively pitching a number of venture capital firms for several months. After some initial traction, one notable but not top-tier VC expressed interest, requested more information, and invited us to a video pitch and an in-person meeting with a partner. Ultimately, they decided not to move forward, citing that the market seemed too broad.
A troubling observation
– One of the VC’s portfolio companies is an indirect competitor in our space. This company has raised several million dollars a few years ago but has not achieved product-market fit or meaningful breakout success.
– About a week after our rejection, I discovered a LinkedIn post announcing a beta waitlist for a product that was indistinguishably aligned with what we had pitched to the VC. In addition, some language from our deck appeared to be replicated in their outreach materials.
– This discovery raised serious questions about the ethics of ideas-sharing between investors and portfolio companies, and the potential for inappropriate use of confidential or non-public information.
Current stance and next steps
– We believe our technical progress and focus remain ahead in many respects, and our team is fully committed to building the product regardless of a single competitor’s actions.
– While this is unsettling, we are not deterred and plan to continue refining our product, engaging investors who demonstrate ethical standards, and seeking constructive feedback from the broader startup community.
Request for input
– Have others encountered similar situations where a portfolio company appears to copy or imitate ideas pitched to its investor? How did you respond, and what strategies helped protect your interests without burning bridges?
– What practical steps can founders take to minimize risk when sharing sensitive concepts during fundraising (e.g., non-disclosure considerations, selective disclosure, competitive intelligence diligence for investors)?
– How should founders balance transparency with risk when discussing competitors for future fundraising rounds?
If you’ve navigated similar circumstances or have perspectives on best practices for ethical conduct in VC relationships, I’d appreciate hearing your experiences and recommendations.
